Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis: results from the SPARTAKUS cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  4. Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Samuel Hawley
  • M Sanni Ali
  • René Cordtz
  • Lene Dreyer
  • Christopher J Edwards
  • Nigel K Arden
  • Cyrus Cooper
  • Andrew Judge
  • Kimme Hyrich
  • Daniel Prieto-Alhambra
Vis graf over relationer

OBJECTIVES: Previous ecological data suggest a decline in the need for joint replacements in RA patients following the introduction of TNF inhibitor (TNFi) therapy, although patient-level data are lacking. Our primary aim was to estimate the association between TNFi use and subsequent incidence of total hip replacement (THR) and total knee replacement.

METHODS: A propensity score matched cohort was analysed using the British Society for Rheumatology Biologics Registry (2001-2016) for RA data. Propensity score estimates were used to match TNFi users to similar conventional synthetic DMARD users (with replacement) using a 1:1 ratio. Weighted multivariable Cox regression was used to estimate the impact of TNFi on study outcomes. Effect modification by baseline age and disease severity were investigated. Joint replacement at other sites was also analysed. An instrumental variable sensitivity analysis was also performed.

RESULTS: The matched analysis contained a total of 19 116 patient records. Overall, there was no significant association between TNFi use vs conventional synthetic DMARD on rates of THR (hazard ratios = 0.86 [95% CI: 0.60, 1.22]) although there was significant effect modification by age (P < 0.001). TNFi was associated with a reduction in THR among those >60 years old (hazard ratio = 0.60 [CI: 0.41, 0.87]) but not in younger patients. No significant associations were found for total knee replacement or other joint replacement.

CONCLUSION: Overall, no association was found between the use of TNFi and subsequent incidence of joint replacement. However, TNFi was associated with a 40% relative reduction in THR rates among older patients.

OriginalsprogEngelsk
TidsskriftRheumatology (Oxford, England)
Vol/bind58
Udgave nummer7
Sider (fra-til)1168-1175
Antal sider8
ISSN1462-0324
DOI
StatusUdgivet - 1 jul. 2019

Bibliografisk note

© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.

ID: 58099107